Tipiracil

• UNSPSC Description:

  Tipiracil is a thymidine phosphorylase (TPase) inhibitor.

• Target Antigen:

  Nucleoside Antimetabolite/Analog; Thymidylate Synthase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Tipiracil.html

• Purity:

  99.98

• Solubility:

  DMSO : < 1 mg/mL (ultrasonic;warming)|H2O : 1 mg/mL (ultrasonic)

• Smiles:

  O=C1NC(C(Cl)=C(CN2C(CCC2)=N)N1)=O

• Molecular Weight:

  242.66

• References & Citations:

  [1]Lee SJ, et al. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1327-35.|[2]Raedler LA. Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):97-100.|[3]Tanaka N, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014 Dec;32(6):2319-26.Oncol Rep. 2023 Mar;49(3):52.|Biomed Pharmacother. 2021 May 6;139:111672.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Mod Rheumatol. 2018 May;28(3):495-505.|Patent. US Patent 11110111.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  183204-74-2